155 related articles for article (PubMed ID: 29844129)
1. Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.
Grisham RN; Moore KN; Gordon MS; Harb W; Cody G; Halpenny DF; Makker V; Aghajanian CA
Clin Cancer Res; 2018 Nov; 24(22):5525-5533. PubMed ID: 29844129
[No Abstract] [Full Text] [Related]
2. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
3. Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer.
Blagden SP; Hamilton AL; Mileshkin L; Wong S; Michael A; Hall M; Goh JC; Lisyanskaya AS; DeSilvio M; Frangou E; Stronach EA; Gopalakrishna P; Meniawy TM; Gabra H
Clin Cancer Res; 2019 Mar; 25(5):1472-1478. PubMed ID: 30563934
[TBL] [Abstract][Full Text] [Related]
4. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Monk BJ; Grisham RN; Banerjee S; Kalbacher E; Mirza MR; Romero I; Vuylsteke P; Coleman RL; Hilpert F; Oza AM; Westermann A; Oehler MK; Pignata S; Aghajanian C; Colombo N; Drill E; Cibula D; Moore KN; Christy-Bittel J; Del Campo JM; Berger R; Marth C; Sehouli J; O'Malley DM; Churruca C; Boyd AP; Kristensen G; Clamp A; Ray-Coquard I; Vergote I
J Clin Oncol; 2020 Nov; 38(32):3753-3762. PubMed ID: 32822286
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
[TBL] [Abstract][Full Text] [Related]
6. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
Oza A; Kaye S; Van Tornout J; Sessa C; Gore M; Naumann RW; Hirte H; Colombo N; Chen J; Gorla S; Poondru S; Singh M; Steinberg J; Yuen G; Banerjee S
Gynecol Oncol; 2018 May; 149(2):275-282. PubMed ID: 29454514
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
9. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer.
Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS
Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570
[TBL] [Abstract][Full Text] [Related]
10. A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses.
Matei D; Ghamande S; Roman L; Alvarez Secord A; Nemunaitis J; Markham MJ; Nephew KP; Jueliger S; Oganesian A; Naim S; Su XY; Keer H; Azab M; Fleming GF
Clin Cancer Res; 2018 May; 24(10):2285-2293. PubMed ID: 29500276
[No Abstract] [Full Text] [Related]
11. Phase 1 Study of Low-Dose Fractionated Whole Abdominal Radiation Therapy in Combination With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer (GCGS-01).
Ngoi NYL; Heong V; Tang JI; Choo BA; Kumarakulasinghe NB; Lim D; Low M; Lim SE; Lim YW; Leong YH; Tseng M; Tong PSY; Ilancheran A; Low JJH; Ng J; Thian YL; Koh V; Tan DSP
Int J Radiat Oncol Biol Phys; 2021 Mar; 109(3):701-711. PubMed ID: 33045316
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.
Kaern J; Baekelandt M; Tropé CG
Eur J Gynaecol Oncol; 2002; 23(5):383-9. PubMed ID: 12440808
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
Rosenbaum E; Kelly C; D'Angelo SP; Dickson MA; Gounder M; Keohan ML; Movva S; Condy M; Adamson T; Mcfadyen CR; Antonescu CR; Hwang S; Singer S; Qin LX; Tap WD; Chi P
Oncologist; 2019 Oct; 24(10):1309-e983. PubMed ID: 31213500
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors.
Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922
[TBL] [Abstract][Full Text] [Related]
15. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
Lauria R; Ferrari E; Tramontana S; Morabito A; Perrone F; Maffeo A; Fiorentino R; Casella G; Iodice F; Ricchi P; Carlomagno C; Varriale E; De Placido G; De Placido S; Bianco AR; Pignata S
Oncology; 1999; 56(4):267-73. PubMed ID: 10343189
[TBL] [Abstract][Full Text] [Related]
17. Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy.
Gregory RK; Hill ME; Moore J; A'Hern RP; Johnston SR; Blake P; Shephard J; Barton D; Gore ME
Eur J Cancer; 2000 Mar; 36(4):503-7. PubMed ID: 10717527
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
19. Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Havrilesky LJ; Alvarez AA; Sayer RA; Lancaster JM; Soper JT; Berchuck A; Clarke-Pearson DL; Rodriguez GC; Carney ME
Gynecol Oncol; 2003 Jan; 88(1):51-7. PubMed ID: 12504627
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of weekly paclitaxel carboplatin induction therapy: an effective and well-tolerated treatment in patients with platinum-resistant ovarian cancer.
van der Burg ME; Vergote I; Onstenk W; Boere IA; Leunen K; van Montfort CA; van Doorn HC
Eur J Cancer; 2013 Apr; 49(6):1254-63. PubMed ID: 23276720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
